SAT0421 Reduction in Fatigue in Patients with Active Ankylosing Spondylitis: Results of Two Phase 3 Studies of Secukinumab

• Published in: Annals of the rheumatic diseases Vol. 75; no. Suppl 2; p. 823
• Main Authors: Kvien, T.K., Conaghan, P.G., Deodhar, A., Gossec, L., Østergaard, M., Cañete, J., Gandhi, K., Richards, H., Williams, N., Jugl, S.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2016

BackgroundPatients with active ankylosing spondylitis (AS) experience fatigue which frequently leads to reduced health-related quality of life (HRQoL). Secukinumab (SEC) treatment results in rapid improvements in signs and symptoms, physical functioning and HRQoL in patients with active AS versus pl...